With Increased Cases Of Immune Disease, Various Clinical Trials and Drug Approvals are Driving the Global Sjogren Syndrome Market

The global Sjogren syndrome market is anticipated to grow at a considerable CAGR of 4.6% during the forecast period. Across the globe, various autoimmune diseases are increasing such as rheumatoid arthritis, and lupus, and among others coupled with it, there is increased demand for advanced treatments and technological solutions for such diseases. Hence, the increasing the cases of these diseases the government authorities are approving treatments and drugs for the diseases and various key players in the market are investing heavily in the development of new drugs for the increasing number of cases and such factors are attributed to augmenting the Sjogren syndrome growth. For instance, 

• In January 2022, OSE Immunotherapeutic obtained IND by Veloxis Pharmaceuticals, Inc from the Food & Drug Administration (FDA). This approval is for a clinical trial with VEL-101/FR104, a CD28 antagonist monoclonal antibody and to develop, manufacture, and commercialize FR104 and also all product rights to develop FR104 in autoimmune disease. 
• In December 2020, GlaxoSmithKline plc, BENLYSTA has received approval from US Food and Drug Administration (FDA), for the treatment of adult patients with active lupus nephritis (LN).
• In February 2020, Dompé farmaceutici S.p.A. and Dompé U.S. Inc., for the patients with severe Sjögren's-related dry eye disease, the companies have been enrolled in its Phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in such diseases. This phase 3 trial is currently no FDA-approved treatment for severe Sjögren's-related dry eye disease.

Browse the full report description “Global Sjogren Syndrome Market Size, Share & Trends Analysis Report by Type (Primary Sjögren’s Syndrome and Secondary Sjögren’s Syndrome), by Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents), and by Test (Blood Test, Eye Test, Imaging Test, and Biopsy) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/sjogrens-syndrome-market 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Drug Type
• By Test

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- AbbVie Inc., Argentis Pharmaceuticals, LLC, AstraZeneca PLC, Bristol-Myers Squibb Co., Novartis International AG, Pfizer Inc., Sanofi S.A., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Sjogren Syndrome Market Report Segment

By Type

• Primary Sjögren’s Syndrome
• Secondary Sjögren’s Syndrome

By Drug Type

• Pilocarpine
• Cyclosporine 
• Hydroxychloroquine
• Immunosuppressive Agents

By Test

• Blood Test
• Eye Test
• Imaging Test
• Biopsy

Global Sjogren Syndrome Market Report by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/sjogrens-syndrome-market